JBJ-04-125-02

• CAT Number: I016830
• CAS Number: 2060610-53-7
• Molecular Formula: C₂₉H₂₆FN₅O₃S
• Molecular Weight: 543.61
• Purity: ≥95%
• Target: Protein Tyrosine Kinase/RTK
• IUPAC Name: (2R)-2-(5-fluoro-2-hydroxyphenyl)-2-[3-oxo-5-(4-piperazin-1-ylphenyl)-1H-isoindol-2-yl]-N-(1,3-thiazol-2-yl)acetamide
• InChI: InChI=1S/C29H26FN5O3S/c30-21-5-8-25(36)24(16-21)26(27(37)33-29-32-11-14-39-29)35-17-20-2-1-19(15-23(20)28(35)38)18-3-6-22(7-4-18)34-12-9-31-10-13-34/h1-8,11,14-16,26,31,36H,9-10,12-13,17H2,(H,32,33,37)/t26-/m1/s1
• InChIKey: VHQVOTINPRYDAO-AREMUKBSSA-N
• SMILES: C1CN(CCN1)C2=CC=C(C=C2)C3=CC4=C(CN(C4=O)[C@H](C5=C(C=CC(=C5)F)O)C(=O)NC6=NC=CS6)C=C3

JBJ-04-125-02（Cat No.:I016830）is a small molecule compound that has been studied for its potential therapeutic effects, particularly in the field of oncology. It is known to act as a selective inhibitor of certain cellular pathways, targeting specific proteins involved in cancer cell growth, survival, and metastasis. Preclinical studies suggest that JBJ-04-125-02 can suppress tumor growth by modulating these pathways, offering a potential treatment for cancers resistant to conventional therapies. Research is ongoing to assess its safety, efficacy, pharmacokinetics, and the potential for clinical use in cancer therapy.

Reference

[1]. To C, et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 Jul;9(7):926-943.